GlobeNewswire Inc | Sep 8, 2020 08:00AM EDT

September 08, 2020

PHILADELPHIA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participation in fireside chats at the following upcoming September investor conferences:

-- Morgan Stanley 18th Annual Global Healthcare Conference on Monday, September 14, 2020 at 3:00 p.m. ET. -- H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 4:30 p.m. ET.

A live webcast of the presentations will be available on the News and Events section of the companys website at www.cabalettabio.com. Following the presentations, a replay of the webcast will be available on the website for 90 days.

About Cabaletta BioCabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabalettas proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Companys lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTesPhase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes Phase 1 clinical trial, please see www.clinicaltrials.gov. The Companys lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts: Anup Marda Chief Financial Officerinvestors@cabalettabio.com

Sarah McCabeStern Investor Relations, Inc.212-362-1200sarah.mccabe@sternir.com